NCT02471105View on ClinicalTrials.gov

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

PHASE4UnknownINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

December 31, 2017

Conditions
Ocular HypertensionGlaucoma
Interventions
DRUG

Preserved Bimatoprost 0.01%

Eye drops solution Topical use Once in the evening 3 months

DRUG

Tafluprost Unit Dose Preservative Free 15microgram/ml

Eye drops solution Topical use Once in the evening 3 months

Trial Locations (7)

3000

RECRUITING

UZ Leuven, Leuven

Unknown

RECRUITING

Hommer Ophthalmology Institute, Vienna

NOT_YET_RECRUITING

San Paolo Hospital, Milan

NOT_YET_RECRUITING

Bietti Foundation, Rome

NOT_YET_RECRUITING

Clinical Research Centre Momorial A. de Rotschild, Geneva

NOT_YET_RECRUITING

Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire

NOT_YET_RECRUITING

Western Eye Hospital, London

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER